Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer.
Multiple studies have reported that analysis of serum and other bodily fluids using surface enhanced laser desorption/ionization time of flight mass spectroscopy (SELDI-TOF-MS) can identify a "fingerprint" or "signature" of spectral peaks that can separate patients with a specific disease from normal control patients. Ultimately, classification by SELDI-TOF-MS relies on spectral differences in position and amplitude of resolved peaks. Since the reproducibility of quantitation, resolution and mass accuracy of the SELDI-TOF-MS, or any high throughput mass spectrometric technique, has never been determined this method has come under some skepticism as to its clinical usefulness. This manuscript describes a detailed design of a three-phase study to validate the clinical usefulness of SELDI-TOF-MS in the identification of patients with prostatic adenocarcinoma (PCA). At the end of this validation study, the usefulness of the general SELDI-TOF-MS approach to identifying patients with PCA will be demonstrated and how it compares with PCA diagnosis by measuring prostate specific antigen.
Grizzle
William E
WE
University of Alabama at Birmingham, Birmingham, AL 35233-0007, USA. grizzle@path.uab.edu
Adam
Bao-Ling L
BL
Bigbee
William L
WL
Conrads
Thomas P
TP
Carroll
Christopher
C
Feng
Ziding
Z
Izbicka
Elzbieta
E
Jendoubi
Moncef
M
Johnsey
Donald
D
Kagan
Jacob
J
Leach
Robin J
RJ
McCarthy
Diane B
DB
Semmes
O John
OJ
Srivastava
Shiv
S
Srivastava
Sudhir
S
Thompson
Ian M
IM
Thornquist
Mark D
MD
Verma
Mukesh
M
Zhang
Zhen
Z
Zou
Zhiqiang
Z
D000230:Adenocarcinoma / Q000097:blood / Q000175:diagnosis*; D000465:Algorithms; D001798:Blood Proteins / Q000032:analysis*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis*; D012107:Research Design; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
D001798:Blood Proteins